Results 161 to 170 of about 51,558 (279)
Avoidance of MAIT cells is an essential determinant of <i>Listeria</i> monocytogenes pathogenesis. [PDF]
Rivera-Lugo R +8 more
europepmc +1 more source
Manufacturing and clinical applications of non‐CAR‐T immune effector cells
Transfusion, EarlyView.
Thane Kubik +2 more
wiley +1 more source
Staging concept for aging management: Definition, mechanism, and coping strategies
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang +6 more
wiley +1 more source
Immunological Interactions Between Gammadelta T Cells and West Nile Virus in the Infected Host. [PDF]
Cimini E +4 more
europepmc +1 more source
YPEL3 functions as a tumor suppressor in HNSCC by inhibiting tumor progression and promoting apoptosis. Mechanistically, it enhances epithelial–immune crosstalk through the CREB1‐mediated CXCL16–CXCR6 axis, facilitating CD8+ T‐cell infiltration and highlighting its potential as a prognostic biomarker and immunotherapy target.
Yalun Li +7 more
wiley +1 more source
A Case of a Novel Perforin Gene Variant in Severe Familial Hemophagocytic Lymphohistiocytosis Type 2 (FHL2). [PDF]
Yamauchi H +13 more
europepmc +1 more source
Structure of perforine and haplophyllidine [PDF]
Z. Sh. Faizutdinova +2 more
openaire +1 more source
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive hematological malignancy with a poor prognosis and limited therapeutic options. ATL cells exhibit aberrant surface glycosylation patterns resulting from dysregulated glycosyltransferase expression, representing a potentially tumor‐specific therapeutic target.
Yuichiro Uchida +7 more
wiley +1 more source
Clinical, biological and cytometric characteristics of two patients with a homozygous A91V<i>PRF1</i> mutation. [PDF]
Perrard N +12 more
europepmc +1 more source

